Bicara Cash from 2010 to 2026
| BCAX Stock | 14.21 0.15 1.07% |
Cash | First Reported 2010-12-31 | Previous Quarter 563.2 M | Current Value 591.3 M | Quarterly Volatility 215.2 M |
Check Bicara Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bicara Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 225.8 K, Net Interest Income of 17.6 M or Interest Income of 17.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.82. Bicara financial statements analysis is a perfect complement when working with Bicara Therapeutics Valuation or Volatility modules.
Bicara | Cash | Build AI portfolio with Bicara Stock |
The evolution of Cash for Bicara Therapeutics Common provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Bicara Therapeutics compares to historical norms and industry peers.
Latest Bicara Therapeutics' Cash Growth Pattern
Below is the plot of the Cash of Bicara Therapeutics Common over the last few years. Cash refers to the most liquid asset of Bicara Therapeutics, which is listed under current asset account on Bicara Therapeutics Common balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Bicara Therapeutics customers. The amounts must be unrestricted with restricted cash listed in a different Bicara Therapeutics account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. Bicara Therapeutics' Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bicara Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Cash | 10 Years Trend |
|
Cash |
| Timeline |
Bicara Cash Regression Statistics
| Arithmetic Mean | 113,452,864 | |
| Geometric Mean | 12,454,354 | |
| Coefficient Of Variation | 189.70 | |
| Mean Deviation | 167,156,850 | |
| Median | 4,158,000 | |
| Standard Deviation | 215,225,478 | |
| Sample Variance | 46322T | |
| Range | 587.2M | |
| R-Value | 0.73 | |
| Mean Square Error | 23241.4T | |
| R-Squared | 0.53 | |
| Significance | 0.0009 | |
| Slope | 31,017,500 | |
| Total Sum of Squares | 741152.1T |
Bicara Cash History
Other Fundumenentals of Bicara Therapeutics
Bicara Therapeutics Cash component correlations
Click cells to compare fundamentals
About Bicara Therapeutics Financial Statements
Bicara Therapeutics investors use historical fundamental indicators, such as Bicara Therapeutics' Cash, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Bicara Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Cash | 563.2 M | 591.3 M | |
| Cash And Short Term Investments | 563.2 M | 591.3 M | |
| Change In Cash | 298.2 M | 177.8 M | |
| Free Cash Flow | -67.3 M | -70.7 M | |
| Begin Period Cash Flow | 265 M | 278.3 M | |
| Total Cashflows From Investing Activities | -10.3 K | -10.9 K | |
| Other Cashflows From Financing Activities | 1.4 M | 1.4 M | |
| Other Non Cash Items | -69.3 K | -65.8 K | |
| Total Cash From Operating Activities | -67.3 M | -70.6 M | |
| Total Cash From Financing Activities | 384.1 M | 234 M | |
| End Period Cash Flow | 563.2 M | 591.3 M | |
| Other Cashflows From Investing Activities | 55.8 K | 49.6 K | |
| Free Cash Flow Yield | (0.09) | (0.10) | |
| Operating Cash Flow Per Share | (1.58) | (1.66) | |
| Free Cash Flow Per Share | (1.58) | (1.66) | |
| Cash Per Share | 8.10 | 8.50 | |
| EV To Operating Cash Flow | (5.53) | (5.80) | |
| EV To Free Cash Flow | (5.52) | (5.80) | |
| Price To Operating Cash Flows Ratio | (11.41) | (11.99) | |
| Price To Free Cash Flows Ratio | (11.40) | (11.97) | |
| Cash Ratio | 24.50 | 25.72 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.15 | 1.11 | |
| Cash Flow Coverage Ratios | (116.48) | (122.31) | |
| Price Cash Flow Ratio | (11.41) | (11.99) | |
| Cash Flow To Debt Ratio | (116.48) | (122.31) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bicara Stock Analysis
When running Bicara Therapeutics' price analysis, check to measure Bicara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicara Therapeutics is operating at the current time. Most of Bicara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicara Therapeutics' price. Additionally, you may evaluate how the addition of Bicara Therapeutics to your portfolios can decrease your overall portfolio volatility.